Comparison of clinical features and treatment optimization of NK/T-cell lymphoma through international collaboration

2022 Fiscal Year Final Research Report

• Project/Area Number: 20K08731
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 54010:Hematology and medical oncology-related
• Research Institution: Mie University
• Principal Investigator: Yamaguchi Motoko 三重大学, 医学系研究科, 寄附講座教授 (50359767)
• Co-Investigator(Kenkyū-buntansha): 鈴木 律朗 島根大学, 学術研究院医学・看護学系, 教授 (20280810)
• Project Period (FY): 2020-04-01 – 2023-03-31
• Keywords: NK/T細胞リンパ腫 / 新世代治療 / RT-2/3DeVIC療法 / 多機関共同研究 / 国際情報交換

Outline of Final Research Achievements

We conducted additional analyses using the data from the multi-institutional observational study (NKEA) for patients with extranodal natural killer/T-cell lymphoma, nasal type (ENKL) diagnosed between 2000 and 2013 in 31 hospitals in Japan. In collaborating with Korean researchers, we constructed a central nervous system (CNS) relapse risk prediction model. We clarified the long-term prognosis and safety, relationship between diagnosis-treatment interval and prognosis, and details of CNS recurrence of new-generation therapy in Japanese patients. From 2022, we are conducting a next observational study (NKEA-Next) for patients with ENKL diagnosed at 44 institutions in Japan between 2014 and 2021.

Free Research Field

血液内科学　悪性リンパ腫

Academic Significance and Societal Importance of the Research Achievements

本研究によりENKLに特化したCNS再発予測モデルが構築されるとともに、ENKL新世代治療の国内実態がさらに明らかにされた。これらの成果は本疾患の罹患率が低い欧米諸国を始め世界的に診療および治療開発の際に参考とされている。NKEA-Next projectの着手が新型コロナウイルス感染症拡大の影響で少し遅れたが、対象拡大、オンラインでの研究者交流など今後持続可能な研究基盤が構築でき、影響を最小化できたと考えている。